Sofia R. Gameiro

National Institutes of Health — United States

Medicine · Health Sciences

32h-index4.5kcitations118works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(71), Immunotherapy and Immune Responses(54), CAR-T cell therapy research(38), Histone Deacetylase Inhibitors Research(20), Immune Cell Function and Interaction(14)

Publications116 total

Abstract B022: Synergistic epigenetic modulation with a TCRβ-targeted IL-2 fusion molecule enhances CD8+ T cell-mediated MHC-I independent tumor control via an antibody-linked mechanism
Cancer Immunology Research·2026
Abstract B021: Alum-anchored IL-12 combined with HDAC inhibition overcomes checkpoint blockade refractory tumors
Cancer Immunology Research·2026
Abstract C014: A novel TCRβ-directed IL-2 fusion molecule promotes stem-like CD8+ T cells with self-renewing properties in the peripheral lymphoid tissue, further expanded by HDAC inhibition to elicit a sustained anti-tumor therapeutic response
Cancer Immunology Research·2026
Mixed-methods pilot feasibility single-arm trial of Beyond Fertility: a brief face-to-face psychosocial intervention to promote patients’ adjustment to the end of unsuccessful fertility treatment
Pilot and Feasibility Studies·2026Open Access
Psychological aspects of infertility among men
Bristol Research (University of Bristol)·2026
660 A novel TCRβ-directed IL-2 fusion molecule promotes memory CD8 <sup>+</sup> T cells with self-renewing properties in tumor ecosystems, further expanded by HDAC inhibition to elicit effective tumor suppression
Regular and Young Investigator Award Abstracts·2025Open Access
168 Increases in peripheral memory T cells with self-renewing properties in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy
Regular and Young Investigator Award Abstracts·2025Open Access
663 Epigenetic modulation synergizes with TCRβ-targeted IL-2 to yield CD8 <sup>+</sup> T cell dependent, MHC-I independent tumor control via an antibody associated mechanism
Regular and Young Investigator Award Abstracts·2025Open Access
631 Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors
Regular and Young Investigator Award Abstracts·2025Open Access
169 Impact of a Vβ6/Vβ10 targeting IL-2 fusion protein (invikafusp alfa) on the peripheral immunome, including stimulation of memory T cells with self-renewing properties, in patients with cancer
Regular and Young Investigator Award Abstracts·2025Open Access
Supplementary Table S4 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Table S5 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Figure S5 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Figure S6 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Data from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Figure S2 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Table S1 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Figure S4 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Figure S3 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
Supplementary Figure S1 from Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy
2025Open Access
page 1 of 6Next →

Frequent Co-authors

James W. Hodge(32), Jeffrey Schlom(24), Karin M. Knudson(12), Kristin C. Hicks(10), James L. Gulley(9), Anna Kwilas(9), Claudia Palena(7), Andressa Ardiani(7), Kwong Y. Tsang(5), Renee N. Donahue(5), Christine M. Minnar(5), Patrick Soon‐Shiong(5), Max M. Wattenberg(4), Soldano Ferrone(4), Caroline Jochéms(4), Anthony S. Malamas(4), Paul L. Chariou(4), Yohei Ozawa(4), Shahrooz Rabizadeh(4), Duane H. Hamilton(4)